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Abstract
Background: Vascular endothelial growth factor (VEGF) has previously been shown to upregulate the expression of the
endogenous calcineurin inhibitor, regulator of calcineurin 1, variant 4 (RCAN1.4). The aim of this study was to determine the
role and regulation of VEGF-mediated RCAN1.4 expression, using human dermal microvascular endothelial cells (HDMECs)
as a model system.
Methodology/Principal Findings: We show that VEGF is able to induce RCAN1.4 expression during cellular proliferation and
differentiation, and that VEGF-mediated expression of RCAN1.4 was inhibited by the use of inhibitors to protein kinase C
(PKC) and calcineurin. Further analysis revealed that siRNA silencing of PKC-delta expression partially inhibited VEGF-
stimulated RCAN1.4 expression. Knockdown of RCAN1.4 with siRNA resulted in a decrease in cellular migration and
disrupted tubular morphogenesis when HDMECs were either stimulated with VEGF in a collagen gel or in an endothelial/
fibroblast co-culture model of angiogenesis. Analysis of intracellular signalling revealed that siRNA mediated silencing of
RCAN1.4 resulted in increased expression of specific nuclear factor of activated T-cells (NFAT) regulated genes.
Conclusions/Significance: Our data suggests that RCAN1.4 expression is induced by VEGFR-2 activation in a Ca
2+ and PKC-
delta dependent manner and that RCAN1.4 acts to regulate calcineurin activity and gene expression facilitating endothelial
cell migration and tubular morphogenesis.
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Introduction
Angiogenesis is defined as the formation of new blood vessels
from pre-existing vessels, and is an essential process in embryonic
development and normal physiology. However, an unbalance in
angiogenesis may play a role in a number of pathological
conditions, including cancer, atherosclerosis, and ischaemia [1].
The vascular endothelial growth factor (VEGF) family of
homodimeric glycoproteins have been shown to be critical for
angiogensis. The VEGF family comprises 5 members; VEGF-A,
VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PLGF).
In addition there are a number of structurally related proteins,
including parapoxvirus Orf VEGF (VEGF-E). These ligands bind
in an overlapping pattern to 3 receptors; VEGF Receptor 1
(VEGFR-1), VEGFR-2 and VEGFR-3 (reviewed in [2]). Vascular
endothelial cells express both VEGFR-1 and VEGFR-2, with
VEGFR-2 generally accepted as the principal receptor through
which VEGF signals are transmitted in the vascular endothelium.
Binding of VEGF to VEGFR-2 results in the activation of a
number of intracellular signalling pathways including mitogen-
activated protein kinases (MAPKs) and protein kinase B (PKB)/
Akt. VEGFR-2 also activates phospholipase C-c (PLCc) leading to
an increase in intracellular calcium and activation of protein
kinase C (PKC; reviewed in [2]).
Proteins within the regulator of calcineurin (RCAN) family are
able to bind and regulate the protein phosphatase calcineurin.
This family comprises 3 members; RCAN1, 2 and 3. RCAN1 was
initially given the name Down syndrome critical region 1 (DSCR1)
due to its location on chromosome 21 [3]. Other names include
Adapt 78, myocyte-enriched calcineurin interacting protein 1
(MCIP1) and calcipressin 1 [4,5,6].
The human RCAN1 gene comprises 7 exons, the first 4 of which
are alternative first exons, resulting in different isoforms which
show different patterns of expression and regulation [7]. Exon one
gives rise to the isoform RCAN1.1 [8]. Exon 2 lacks a methionine
start site required for translation, and exon 3 encodes just 3 amino
acids [7]. Exon 4 gives rise to the isoform RCAN1.4, and is under
the control of a calcineurin responsive promoter, comprising
multiple consensus binding sites for the transcription factor nuclear
factor of activated T-cells (NFAT) [9] and GATA-2/3 sites [10].
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(AP-1) transcription factors have been identified in the region
flanking exon 4 [11].
The serine/threonine protein phosphatase 2B (PP2B)/calci-
neurin is a heterodimer composed of a calcineurin catalytic subunit
A (CnA), and a calcineurin regulatory subunit B (CnB). Upon Ca
2+
induced activation, CnA dephosphorylates members of the NFAT
family [12]. This dephosphorylation allows the translocation of
NFAT to the nucleus where it binds to the NFAT consensus
sequence present in the promoter region of various genes, including
RCAN1.4, resulting in an increase in transcription [12]. RCAN1.4
binds to the catalytic domain within CnA and inhibits its activity
[5,6,13,14]. Phosphorylation of RCAN1.4 by MAPK and glycogen
synthase kinase 3 (GSK-3), allows RCAN1.4 to act as a substrate for
CnA [15]. Thus, RCAN1.4 has been suggested to act as a negative
feedback inhibitor for CnA signalling.
RCAN1 has previously been shown to be upregulated in a
variety of endothelial cell lines in response to VEGF, including
human umbilical vein endothelial cells (HUVEC), human aortic
endothelial cells (HAEC), human dermal microvascular endothe-
lial cells (HDMEC), and human retinal endothelial cells (HREC)
[10,16,17]. In each of these studies RCAN1.4, but not RCAN1.1
was found to be upregulated in response to VEGF treatment.
Knockdown of RCAN1 in endothelial cells has also been shown to
inhibit VEGF stimulated migration in vitro, and VEGF induced
angiogenesis, in vivo [16]. Most recently, an increase in Rcan1
expression in mice, by the introduction of an extra transgenic
copy, has been shown to suppress tumour growth [18]. In this
study, we have analysed the intracellular signalling pathways
utilised by VEGFR-2 to stimulate RCAN1.4 expression in primary
human dermal microvascular endothelial cells (HDMECs). Our
results show that the calcineurin/NFAT pathway and PKC-delta
pathway are required for maximal induction of RCAN1.4.
Furthermore, RCAN1.4 was required for migration and efficient
tubular morphogenesis in these cells.
Materials and Methods
Materials
Recombinant human VEGF-A165, epidermal growth factor
(EGF), hepatocyte growth factor (HGF) and colony stimulating
factor-1 (CSF-1) were obtained from Peprotech. Recombinant
human VEGF-B167 and recombinant Orf virus VEGF-E were
obtained from Promokine. Fibroblast growth factor-2 (FGF-2) was
obtained from R&D Systems. Phorbol-12-myristate-13-acetate
(PMA), A23187, GF109203X (GFX), Go ¨6976, Cyclosporin A
(CsA) and BAPTA-AM were obtained from Calbiochem.
ZM323881 was obtained from Tocris. Oleoyl-L-a-lysophosphati-
dic acid (LPA) and ethylene glycol tetraacetic acid (EGTA) were
obtained from Sigma. All other materials were obtained from
Invitrogen unless otherwise stated.
Cell Culture
Human dermal microvascular endothelial cells (HDMEC),
human umbilical vein endothelial cells (HUVEC) and human
aortic endothelial cells (HAEC) were purchased from Promocell
and were cultured in endothelial cell basal media (EBM) MV2
growth media (C-22221; Promocell), supplemented with 5% (v/v)
foetal calf serum (FCS) and EGF (5 ng/ml), VEGF (0.5 ng/ml),
FGF-2 (10 ng/ml), long R3 insulin growth factor-1 (20 ng/ml),
hydrocortisone (0.2 mg/ml) and ascorbic acid (1 mg/ml) (supple-
ment pack C-39221; Promocell). HEK 293 cells were cultured in
Dulbecco’s’ Modified Eagles Medium (DMEM) supplemented
with 10% FCS. Human dermal fibroblasts were obtained from
Promocell, and cultured in fibroblast growth media (C-23010;
Promocell) supplemented with FGF-2 (1 ng/ml) and Insulin
(5 mg/ml) (supplement pack; Promocell). Cells were routinely
cultured on gelatin coated plates in a humidified incubator under
5% CO2 at 37uC. For growth factor stimulation, cells were serum
starved for at least 16 hours by changing media to MV2 media
supplemented with 1% (v/v) FCS without growth factor
supplements.
Quantitative Real Time-Polymerase Chain Reaction
(RT-qPCR)
Total RNAwasextractedfrom HDMECs usingthe RNeasymini
kit (Qiagen). DNase treatment was performed using the on-column
DNase digestion (Qiagen). One mg total RNA was used for cDNA
synthesis with M-MLV reverse transcriptase and oligodT primers.
RT-qPCR was performed using Power SYBR Green Mastermix
(Applied Biosystems) and the primer sequences as detailed below.
Reactions were analysed on an ABI 7000 real-time PCR machine
using the following cycle conditions; 2 minutes at 50uC, 10 minutes
at 95uC, followed by 45 cycles of 15 seconds at 95uC and 60 seconds
at 60uC. Results were normalised against b-actin mRNA expression.
Primer sequences were as follows; RCAN1.4 forward –CTCAC-
TAGGGGCTTGACTGC, reverse - CAGGCAATCAGGGAGC-
TAAA; RCAN1.1 forward – TCATTGACTGCGAGATGGAG,
reverse – TGATGTCCTTGTCATACGTCCT; COX-2 forward
– GAAGAAAGTTCATCCCTGATCCC, reverse – CTGGGCA-
AAGAATGCAAACA; IL-8 forward – CAGGAATTGAATGGG-
TTTGC, reverse – AGCAGACTAGGGTTGCCAG; ICAM-1
forward – CAAGGCCTCAGTCAGTGTGA, reverse – CCTC-
TGGCTTCGTCAGAATC.
Immunoblotting
Protein lysates from HDMECs were prepared in LDS sample
buffer containing b-mercaptoethanol. Proteins were resolved by
SDS-PAGE on 4–12% NuPage Gels, and transferred onto
nitrocellulose membranes (Amersham). Membranes were blocked
with 5% (w/v) BSA. Proteins were detected using the following
antibodies; RCAN1 (D6694; Sigma), NFAT1 (610702; BD
Transductions Labs), phospho-p44/42 MAPK (Thr202/Tyr204;
#4377), phospho-PKC (pan; #9371), phospho-PLCc (Tyr 783;
#2821), PKCa (#2056), PKCd (,2058; all Cell Signalling
Technology), PKCe (06-991; Upstate), PKCg (sc-215), colony
stimulating factor-1 receptor (CSF-1R; sc-13949) and Actin (sc-
1625; all Santa Cruz Biotechnology). Membranes were washed 6
times with TBS-T, and incubated with peroxidise-conjugated
secondary antibodies (Amersham/Sigma). Blots were detected
using an enhanced chemiluminescence (ECL) detection kit
(Amersham).
siRNA transfection
HDMECs were transfected with either two separate small
interfering RNA (siRNA) duplexes at a concentration of 10 nM,
or a mixture of two siRNA duplexes at a concentration of 10 nM
each, using 0.1% (v/v) Lipofectamine RNAiMAX, according to the
manufacturer’s instructions. All siRNA duplexes were validated by
RT-qPCR and western blotting prior to use [19]. Transfection
reactions were performed in serum-free OptiMEM. Cell media was
changed to serum containing media 4 hours after transfection. The
following siRNA duplexes were obtained from Qiagen; RCAN1
(Hs_DSCR1_5 HP, SI03224900; Hs_DSCR1_6 HP, SI03246208),
PKCa (Hs_PRKCA_5 HP, SI00301308; Hs_PRKCA_6, HP
SI00605927), PKCd (Hs_PRKCD_8 HP, SI00288337;
Hs_PRKCD_11 HP, SI02660539), PKCe (Hs_PRKCE_5 HP,
Regulation of RCAN1.4 by VEGF
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(Hs_PRKCH_5, SI02224075; Hs_PRKCH_6 HP, SI02224082)
and All-stars Negative Control siRNA.
Overexpression of Chimeric Receptors
The pcDNA3.1 mammalian expression plasmids encoding the
extracellular domain of human CSF-1 receptor (CSF-1R)/c-fms
fused to the transmembrane and intracellular domain of murine
VEGFR-2 (CKRwt) and murine VEGFR-2 Y1173F point
mutation (CKR Y1173F mutant) were kindly provided by Dr.
Nader Rahimi (Boston University, Boston, MA). HDMEC were
combined with the plasmid DNA and HMVEC-L Nucleofector
TM
solution (AMAXA) according to the manufacturer’s instructions
and transfected using program S-05 on the AMAXA Nucleofec-
tor
TM. Cells were then transferred to cell culture dishes and
allowed to adhere in 1% FCS containing media overnight.
Intracellular Calcium Measurements
HDMECs plated upon glass based cell culture dishes (Iwaki)
were loaded with the Ca
2+ indicator dyes Fluo-4-AM (5 mM) and
Fura Red-AM (5 mM) for 20 minutes. Intracellular calcium was
monitored using fluorescent microscopy to measure the emission
ratio of Fluo-4/Fura Red.
Inositol Phosphate assay
PLC activity was determined by measuring the agonist-
stimulated accumulation of [
3H]inositol phosphates in the
presence of 20 mM LiCl from [
3H]myo-inositol labelled cells as
previously described [20].
Cellular Proliferation Assay
HDMECs were seeded in 24 well plates in normal growth
media for 24 hours. Media was then changed to 1% (v/v) FCS
containing media for 24 hours. Cells were stimulated with VEGF
(50 ng/ml) for 72 hours, and the number of viable cells
determined using a luminescent based Cell-titre glo assay
(Promega).
Scratch Wound Migration Assay
HDMECs were seeded in 12 well plates in normal growth
media for 48 hours. Media was then changed to 1% (v/v) FCS
containing media for 24 hours. A scratch was introduced to the
cell monolayer using a sterile 200 ml pipette tip. Cells were
stimulated with VEGF (50 ng/ml) for 18 hours. The cells were
then fixed with 2% (w/v) paraformaldehyde and then stained with
0.5% (w/v) crystal violet solution to allow enhanced imaging.
Tube Formation Assay
Collagen gels were prepared by mixing bovine collagen type-I
(Vitrogen) with 0.1 M NaOH and 10x Ham’s F-12 media
(Promocell) in the ratio 8:1:1, and supplemented with 20 mM
HEPES, 0.117% (w/v) bicarbonate solution, and 2 mM Gluta-
max-I. HDMEC were starved in 1% (v/v) FCS containing media
for 24 hours prior to being seeded onto pre-prepared collagen gels.
Once cells had adhered, a top layer of collagen was added and
allowed to set. Cells were then stimulated with growth factors in
1% (v/v) FCS containing media for 20 hours to induce tubular
morphogenesis. Collagen gels were fixed with 2% (w/v) parafor-
maldehyde and cells visualized by phase contrast microscopy.
Co-culture Assay
Human dermal fibroblasts were seeded in 24 well plates, and
allowed to become confluent. On day 4 HDMEC were seeded
upon the fibroblast monolayer. Co-cultures were serum starved,
and then stimulated with VEGF for 5 days. To assess the effects of
gene knockdown siRNA transfections were performed upon days
3, 5 and 8. In order to visualise tube formation by HDMEC co-
cultures were fixed with 70% (v/v) ethanol, and then stained with
the endothelial specific marker CD31 (Dako) [21].
Statistics
Results are expressed as mean 6 standard deviation (S.D.).
Statistical analyses were performed using an unpaired Student’s t-
test. Statistical significance was set at a P-value less than 0.05 (*), or
0.01 (**).
Results
VEGF-A, PMA and A23187 stimulate an increase in
RCAN1.4 expression in HDMEC
Human RCAN1 comprises seven exons, the first four of which
are alternatively spliced to give rise to different isoforms (Fig. 1A).
Quantitative RT-PCR was used to analyse the expression of
RCAN1.1 and RCAN1.4 mRNA in response to VEGF-A in
HDMECs. Under basal conditions, the amount of RCAN1.4
mRNA was found to be 100-fold greater than the amount of
RCAN1.1 mRNA (data not shown). Following VEGF-A stimula-
tion, levels of RCAN1.4 mRNA were increased 8-fold (Fig. 1B);
RCAN1.1 mRNA levels were not increased by VEGF-A stimula-
tion (Fig. 1B). The expression of RCAN1.1 protein, which was
practically undetectable on a western blot using an antibody to the
C-terminal of RCAN1 which is able to detect all RCAN1
isoforms, did not increase upon VEGF-A stimulation (data not
shown).
Vascular endothelial cells express both VEGFR-1, and
VEGFR-2, both of which are receptors for VEGF-A. Expression
of both receptors in HDMEC was confirmed by PCR (data not
shown). In order to establish the role of each receptor in RCAN1.4
upregulation, VEGF-B and VEGF-E, which bind VEGFR-1 and
VEGFR-2 respectively, were used to stimulate HDMEC. VEGF-B
did not elicit an RCAN1.4 upregulation, while VEGF-E was able
to induce a similar increase in RCAN1.4 expression as VEGF-A at
both the mRNA and protein level (Fig. 1C and D). For the
purposes of this study, all further experiments were conducted
using VEGF-A.
In contrast to VEGF-A, stimulation of HDMECs with a range
of growth factors (FGF-2, EGF and HGF), and the G-protein
agonist LPA did not evoke an increase in RCAN1.4 mRNA
(Fig. 1E) or RCAN1.4 protein (Fig. 1F); active signalling by all
growth factors was confirmed by MAPK phosphorylation. VEGF-
A was also unique in its ability to stimulate PLC-c phosphorylation
and NFAT activation (Fig. 1F). A23187, a Ca
2+ ionophore, and
PMA, a potent PKC activator, were capable of inducing increased
RCAN1.4 mRNA (Fig. 1E) and increased RCAN1.4 protein levels
in the absence of increased PLC-c phosphorylation (Fig. 1F).
Interestingly, unlike VEGF-A and A23187, PMA did not appear
to stimulate the dephosphorylation of NFAT.
RCAN1.4 is downstream of PLC-c, PKC and Ca
2+/
Calcineurin
The ability of VEGF-A to uniquely stimulate PLC activity in
HDMECs compared with other growth factors was verified by
analysing the generation of inositol phosphates (Fig. 2A). This data
correlates with the finding that increases in intracellular Ca
2+ were
only observed following stimulation with VEGF-A and A23187, a
Ca
2+ ionophore (Fig. 2B).
Regulation of RCAN1.4 by VEGF
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following VEGF-A stimulation, allows the binding and subsequent
phosphorylation of PLC-c [22]. PLC-c is then able to catalyze the
hydrolysis of the membrane phospholipid phosphatidylinositol
(4,5)-bisphosphate (PIP2) resulting in the generation of diacylgly-
cerol (DAG), and inositol 1,4,5-trisphosphate (IP3). DAG is a
physiological activator of PKC, whilst IP3 acts upon the
endoplasmic reticulum to release calcium stores, resulting in a
rise in intracellular calcium ([Ca
2+]i). In order to further assess the
importance of PLC-c activation by VEGFR-2 in the increase of
RCAN1.4 expression, HDMECs were transiently transfected
using AMAXA nucleofection with plasmids encoding chimeric
receptors, comprising the extracellular domain of the human CSF-
1R fused with the transmembrane and intracellular domain of the
murine VEGFR-2 (Flk-1; Fig. 3A) [23,24]. Two forms of the
chimeric receptor were used; the wild-type (CKRwt), and a
mutated form in which the tyrosine residue at position 1173
(corresponding to position 1175 in the human receptor) is replaced
with a phenylalanine residue (CKR Y1173F). In cells expressing
CKRwt, CSF-1 ligand may be used to elicit a VEGF-A-like
Figure 1. VEGF-A stimulates RCAN1.4 expression, PLC-c activation and NFAT dephosphorylation in HDMEC. (A) Exon structure of
RCAN1, showing the alternative first exons used by the RCAN1.1 and RCAN1.4 isoforms. (B) HDMEC were stimulated with VEGF-A (50 ng/ml) for
1 hour, and the increase in expression of RCAN1.1 and RCAN1.4 mRNA, relative to the level of each mRNA in unstimulated (basal) cells, determined by
RT-qPCR. Results were normalised to b-actin mRNA expression. Data shows mean 6 SD (n=3). **P,0.01, versus Basal. (C) HDMEC were stimulated
with VEGF-A (50 ng/ml), VEGF-B (50 ng/ml), VEGF-E (50 ng/ml) or VEGF-B and –E (50 ng/ml each) for 1 hour and the expression of RCAN1.4 mRNA
determined by RT-qPCR. Results were normalised to b-actin mRNA expression. Data shows mean 6 SD (n=3). **P,0.01, versus Basal. (D) HDMEC
were stimulated with agonists as in 1C for 10 mins or 3 hours and the expression levels of RCAN1.4 (3 hour stimulation), and phospho-VEGFR2
(pVEGFR2) proteins determined by SDS-PAGE followed by western blotting. Actin was used as a loading control. Numbers below the blots denote the
relative density of each band. Results are representative of 3 experiments. (E) HDMEC were stimulated with VEGF-A (50 ng/ml), FGF-2 (50 ng/ml), EGF
(50 ng/ml), HGF (50 ng/ml), LPA (10 mM), A23187 (5 mM) and PMA (100 nM) for 1 hour, and the expression of RCAN1.4 mRNA, relative to unstimulated
(basal) cells, determined by RT-qPCR. Results were normalised to b-actin mRNA expression. Data shows mean 6 SD (n=3). **P,0.01, versus Basal. (F)
HDMEC were stimulated with agonists as in 1C for 10 mins or 3 hours and the expression levels of RCAN1.4 (3 hour stimulation), phospho–PLCc (p-
PLCc), NFAT and phospho-p44/42 MAPK (p-MAPK) proteins determined by SDS-PAGE followed by western blotting. Actin was used as a loading
control. Numbers below the blots denote the relative density of each band. Results are representative of 3 experiments.
doi:10.1371/journal.pone.0011435.g001
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binding to tyrosine residue 1173. However, in cells expressing
CKR Y1173F, stimulation with CSF-1 can no longer elicit PLC-c
phosphorylation. Expression of the chimeric receptors was
confirmed by western blotting with an antibody to the extracel-
lular domain of CSF-1R, and active signalling confirmed by the
phosphorylation of PLC-c and MAPK in response to the ligand
CSF-1 (Fig. 3B). Phosphorylated PLC-c was observed in CKRwt
transfected cells in response to CSF-1 stimulation. This phosphor-
ylation was lost in cells transfected with the CKR Y1173F mutant
confirming that PLC-c was not activated by the CKR Y1173F
receptor.
The importance of PLC-c activation in the upregulation of
RCAN1.4 mRNA was assessed by RT-qPCR (Fig. 3C). In cells
transfected with CKRwt, levels of RCAN1.4 mRNA were found to
be upregulated when stimulated with CSF-1 to a similar
magnitude as that seen when stimulating with VEGF. However,
in cells transfected with CKR Y1173F, stimulation with CSF-1 did
not induce a rise in the levels of RCAN1.4 mRNA. Stimulating
untransfected cells with CSF-1 did not induce an increase in
RCAN1.4 mRNA, consistent with the lack of expression of
endogenous CSF-1R in these cells.
A range of inhibitors were used to further investigate the
signalling pathways resulting in the upregulation of RCAN1.4 by
VEGF-A (Fig. 4A). Use of ZM323881, an inhibitor to VEGFR-2
[25], inhibited RCAN1.4 upregulation, confirming further that
upregulation of RCAN1.4 by VEGF-A was occurring through
VEGFR-2 signalling. BAPTA and EGTA, chelators of intracel-
lular and extracellular calcium respectively [26], were both found
to inhibit VEGF-A induced RCAN1.4. GF109203X, a broad
spectrum PKC inhibitor [27] was found to inhibit VEGF-A
induced RCAN1.4, whilst Go ¨6976, a classical PKC inhibitor [28],
did not, implicating a novel PKC in the upregulation of RCAN1.4
expression. Finally cyclosporin A (CsA), a potent inhibitor of
calcineurin [29], was found to block VEGF-A induced RCAN1.4.
Figure 2. VEGF-A stimulates PLC activity and Ca
2+ release. (A)
HDMEC were stimulated with VEGF-A (50 ng/ml), FGF-2 (50 ng/ml), EGF
(50 ng/ml), HGF (50 ng/ml), LPA (10 mM), A23187 (5 mM) and PMA
(100 nM) for 30 mins, and PLC activity determined by inositol
phosphate assay. Data shows mean 6 SD (n=3). **P,0.01, versus
Basal. (B) HDMEC were loaded with Fluo4 and Fura Red dyes and
stimulated with agonists as in 2A and changes in intracellular calcium
monitored by measuring the fluorescent intensity of the two dyes.
Results are representative of 3 experiments.
doi:10.1371/journal.pone.0011435.g002
Figure 3. Induction of RCAN1.4 requires phosphorylation of
Y1175 on VEGFR-2. (A) Structure of chimeric receptors used to
transfect HDMEC. (B) HDMEC were transfected with chimeric receptors
and stimulated with CSF-1 (C; 50 ng/ml) or VEGF-A (V; 50 ng/ml) for
10 mins. The levels of CSF-1R, phospho-PLCc (p-PLCc) and phospho-
p44/42 MAPK (pMAPK) were determined by SDS-PAGE followed by
western blotting. Actin was used as a loading control. Numbers below
the blots denote the relative density of each band. Results are
representative of 3 experiments. (C) HDMEC were transfected with
chimeric receptors, stimulated with CSF-1 (50 ng/ml) or VEGF-A (50 ng/
ml) for 1 hour, and the expression of RCAN1.4 mRNA, relative to
unstimulated vector transfected cells, determined by RT-qPCR. Results
were normalised to b-actin mRNA expression. Data shows mean 6 SD
(n=3). **P,0.01, versus unstimulated vector control.
doi:10.1371/journal.pone.0011435.g003
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2+, calcineurin and PKC in the
pathway linking VEGFR-2 to RCAN1.4 expression.
ThesameinhibitorswereusedincombinationwithPMA(Fig.4B)
and A23187 (Fig. 4C). As expected GF109203X inhibited PMA
stimulation of RCAN1.4. However, as with VEGF-A, Go ¨6976 did
not affect PMA stimulated RCAN1.4 expression. The use of CsA
supported our previous data (Fig. 1D), showing that PMA is not
acting through the calcineurin pathway to stimulate expression of
RCAN1.4. A23187 induction of RCAN1.4 was inhibited by the
Ca
2+ chelators, and by CsA, but not by PKC inhibitors. Use of the
MEK1 inhibitor U0126 [30] did not affect RCAN1.4 induction by
VEGF, PMA or A23187, suggesting that RCAN1.4 is not
downstream of the MEK-p44/p42 MAPK pathway.
PKCd is required for induction of RCAN1.4
The phosphorylation of different PKC isoforms following
stimulation with VEGF-A, FGF-2, PMA or A23187 was
investigated using a pan-phospho PKC antibody (Fig. 5). The
antibody used detects serine residues within the hydrophobic
regions of PKCa, d, e and g, the phosphorylation of which is
required for PKC activation [31]. PKCa, d, e and g were all
rapidly phosphorylated in response to VEGF-A. However, only
the phosphorylation of PKCd was found to be sustained above
basal levels over a 60 minute period, while the phosphorylation of
PKC a, e and g were found to return to basal levels within 30
minutes (Fig. 5). In response to FGF-2 stimulation, small transient
increases in the phosphorylation of PKCa, PKCe and PKCg were
observed (Fig. 5). As with VEGF-A, the phosphorylation of these
isoforms returned to basal levels within 30 minutes of stimulation.
Similar data to FGF-2 was obtained when stimulating HDMECs
with EGF (data not shown). In response to PMA, the
phosphorylation of all PKC isoforms is sustained over 60 minutes.
In contrast, in response to A23187 the PKCs were seen to undergo
a weak transient phosphorylation.
Use of the PKC activator, PMA, and PKC inhibitors,
GF109203X and Go ¨6976, implicated the involvement of a novel
PKC in the upregulation of RCAN1.4. PKC is a multi-protein
family, comprising several isoforms [32]. The classical isoforms a, b,
and c have a requirement for Ca
2+ and DAG for activity, whereas
the novel isoforms d, e, g and h require DAG but not Ca
2+. A third
class of atypical isoforms require neither Ca
2+ nor DAG. The PKC
expression profile in HDMECs was characterised using end-point
PCR, and visualised on an agarose gel (Fig. 6A). The PKC profile of
293 cells was also characterised as a positive control for the primer
sets used. HDMECs were found to express the classical PKC
isoform a, the novel isoforms d, e,a n dg, and the atypical isoform i.
HDMEC were transfected with siRNAs to the expressed
classical (a) and novel isoforms (d, e and g) using non-silencing
(N.S.) siRNA as a control. The knockdown of each isoform was
confirmed by western blotting (Fig. 6B). Knockdown of each
isoform was quantified by RT-qPCR, and found to be between 80
and 90% (data not shown). Knockdown of PKCd was found to
reduce VEGF-A upregulation of RCAN1.4 mRNA by approxi-
mately 50% (Fig. 6C). Knockdown of other PKC isoforms present
in HDMECs did not affect VEGF-A upregulation of RCAN1.4.
This was confirmed at the protein level by western blotting, with a
40% reduction in RCAN1.4 protein observed following PKCd
knockdown (Fig. 6D). Knockdown of PKCd was not found to
decrease the ability of PMA to stimulate RCAN1.4. However,
knockdown of PKCe reduced PMA stimulated RCAN1.4 mRNA
(Fig. 6C), and reduced protein levels by 40% (Fig. 6D).
In order to confirm that the role of PKCd in VEGF-A
stimulated upregulation of RCAN1.4 is not confined to HDMEC,
PKCd knockdown was also performed in HUVEC and HAEC
using two separate PKCd specific siRNA duplexes (Fig. 6E). In all
3 endothelial cell lines knockdown of PKCd resulted in an
approximate 50% reduction in RCAN1.4 expression in response
to VEGF-A. In addition, CsA was successfully used to inhibit
RCAN1.4 upregulation in all 3 cell lines (Fig. 6E).
Knockdown of RCAN1.4 affects expression of NFAT
regulated genes
RCAN1.4 has previously been shown to regulate calcineurin
signalling via a negative feedback loop [5,6,9]. In order to
investigate the role of RCAN1.4 in the regulation of VEGFR-2
signalling we utilised siRNA against RCAN1 and analysed
signalling and gene expression in response to VEGF-A. Due to
Figure 4. RCAN1.4 induction requires Ca
2+, calcineurin and PKC
activity. HDMEC were incubated with the inhibitors ZM (3 mM), BAP
(20 mM), EGTA (2.5 mM), GFX (3 mM), Go (3 mM). CsA (100 nM) or U0126
(5 mM) for 30 minutes, and then stimulated with: (A) VEGF-A (50 ng/ml),
(B) PMA (100 nM), or (C) A23187 (5 mM) for 1 hour. Expression of
RCAN1.4 mRNA, relative to unstimulated (basal) cells, was determined
by RT-qPCR. Results were normalised to b-actin expression. Data shows
mean 6 SD (n=3). **P,0.01, versus VEGF/PMA/A23187 treated. BAP –
BAPTA/AM, CsA – cyclosporin A, GFX - GF109203X, Go – Go ¨6976, ZM –
ZM323881.
doi:10.1371/journal.pone.0011435.g004
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two duplexes used in this study are capable of knocking down the
expression of both RCAN1 isoforms. Since RCAN1.4 is the only
detectable isoform and is VEGF-inducible, we attribute the effects
of the siRNA on VEGF signalling to changes in RCAN1.4
expression. Efficient knockdown of RCAN1.4 was confirmed at
the protein level by western blotting (Fig. 7A) and at the mRNA
level by qRT-PCR with a 90% reduction in mRNA compared
with the N.S. siRNA control (data not shown). No effect of
RCAN1.4 knockdown was observed on the phosphorylation of
PLC-c and MAPK in response to VEGF (Fig. 7A). In order to
analyse the effect of RCAN1.4 silencing on gene expression we
chose a panel of NFAT-regulated genes: COX-2 [33], IL-8 [34]
and ICAM-1 [35]. RCAN1.4 knockdown increased the expression
of COX-2, IL-8 and ICAM-1 mRNA in response to VEGF-A
(Fig. 7B), confirming that RCAN1.4 acts as a negative regulator of
NFAT-mediated gene expression.
Knockdown of RCAN1.4 affects cellular migration and
tubular morphogenesis, but not cellular proliferation
It has previously been shown that plating telomerase-immortal-
ised HDMEC onto either a collagen or fibronectin matrix causes
the cellsto respond differently [36]. Upon a collagen matrix the cells
undergo tubular morphogenesis in response to VEGF-A stimula-
tion,whereasona fibronectin matrixthecellsproliferateinresponse
to VEGF-A. In our studies, we have used gelatin, rather than
fibronectin, as a similar proliferative behaviour was exhibited upon
each matrix. The expression of RCAN1.4 mRNA in response to
VEGF-A upon collagen and gelatin matrices over a 24 hour period
was determined using RT-qPCR (Fig. 8A). RCAN1.4 mRNA
expression was increased upon both matrices. However, the
increase in expression was greater on the collagen matrix, as
opposed to the gelatin matrix. In addition, the expression of
RCAN1.4 mRNA was sustained for 24 hours on collagen, whereas
on the gelatin matrix expression levels had returned to close to basal
levels within 24 hours. A similar pattern of RCAN1.4 expression
was observed at the protein level on both matrices (Fig. 8B).
To investigate the role of RCAN1.4 in cellular proliferation in
response to VEGF-A stimulation RCAN1.4 expression was
knocked down using siRNA and the extent of cellular proliferation
over 72 hours was determined. In untransfected cells there was an
80% increase in cell number following VEGF-A stimulation,
compared to those cells left in basal conditions. Knockdown of
RCAN1.4 in HDMECs did not impact upon cellular proliferation
in response to VEGF-A (Fig. 9A).
The role of RCAN1.4 in cellular migration was determined using
a scratch wound migration assay, in which RCAN1.4 expression
was knocked down, and the ability of the cells to migrate into a
scratched wound inresponseto VEGF-Astimulationwas quantified
(Fig. 9B). Following knockdown of RCAN1.4 the ability of
HDMEC to migrate into the wound was reduced by 80%,
indicating a role for RCAN1.4 in endothelial cell migration.
The importance of RCAN1.4 expression in tubular morpho-
genesis was assessed using two in vitro models of angiogenesis.
Firstly, the cells were plated within a collagen gel, and stimulated
with VEGF-A (Fig. 9C). The ability of cells to form tubes was
determined by measuring the total cellular junctions using
AngioQuant software [37]. In response to VEGF-A, the number
of cellular junctions increased by 85%, when compared with
unstimulated cells. However, when cells were transfected with
siRNA to RCAN1.4 their ability to undergo tubular morphogen-
esis was impaired. Under basal conditions the number of cellular
junctions was reduced by 70%. Though VEGF-A was able to
induce an increase in tubular morphogenesis in cells transfected
Figure 5. PKCd phosphorylation is sustained in response to VEGF-A. HDMEC were stimulated with VEGF-A (50 ng/ml), FGF-2 (50 ng/ml) PMA
(100 nM) or A23187 (5 mM) for the time points indicated. The expression levels of phospho-PLCc (p-PLCc), phospho-PKC (p-PKC) and phospho-p44/
42 MAPK (p-MAPK) were determined by SDS-PAGE followed by western blotting. Actin was used as a loading control. Graphs show the relative
expression of each phosphorylated PKC isoform in response to either VEGF-A, FGF-2 or PMA, as determined from the relative density of the bands
compared to the unstimulated (basal) condition. Results are representative of 3 experiments.
doi:10.1371/journal.pone.0011435.g005
Regulation of RCAN1.4 by VEGF
PLoS ONE | www.plosone.org 7 July 2010 | Volume 5 | Issue 7 | e11435with RCAN1.4 siRNA, compared to unstimulated cells, it did not
exceed the level seen in untransfected basal cells.
To further investigate the importance of RCAN1.4 in tubular
morphogenesisa second in vitro assaywas utilised,inwhich HDMEC
were cultured in combination with human dermal fibroblast cells
[21]. As with the collagen assay, the ability of HDMECs to undergo
tubular morphogenesis in response to VEGF-A was impaired
following knockdown of RCAN1.4 (Fig. 9D). Taken together, the
data from the collagen gel assay and co-culture assay suggest that
RCAN1.4 is required for efficient tubular morphogenesis.
Discussion
VEGF-A has previously been shown to upregulate RCAN1.4
expression in endothelial cells, triggering a negative feedback loop
which regulates the activity of calcineurin, and results in decreased
angiogenesis [10,17,38]. It has been previously assumed that
VEGF-A is able to regulate RCAN1.4 expression by activation of
the classical Ca
2+/calcineurin pathway leading to activation of the
NFAT transcription factor; the potential involvement of other
signalling pathways has not been investigated. We now show that
in addition to the Ca
2+/calcineurin pathway, VEGF-A also utilises
PKCd in the regulation of RCAN1.4 expression. In addition, we
show that RCAN1.4 is required for efficient tubular morphogen-
esis in two in vitro assays of angiogenesis, including a co-culture
model.
RCAN1.4 was found to be upregulated at both the mRNA and
the protein level in response to VEGF treatment (Fig. 1B).
Although RCAN1.1 has also been reported to be upregulated in
HUVECs in response to VEGF [39], we did not see upregulation
of RCAN1.1 in HDMECs. Furthermore, basal levels of RCAN1.1
mRNA were 100-fold lower than basal levels of RCAN1.4 mRNA,
and RCAN1.1 expression was practically undetectable on a
western blot. VEGF-A and VEGF-E, but not VEGF-B induced
Figure 6. VEGF-A mediated RCAN1.4 expression is regulated by PKCd. (A) PKC isoforms present in HDMEC and 293 cells were quantified by
endpoint PCR run on an agarose gel. Results are representative of 3 experiments (B) HDMEC were transfected with a mixture of two siRNAs to
individual PKC isoforms or with non-silencing (N.S.) siRNA, and the knockdown confirmed by SDS-PAGE followed by western blotting. Actin was used
as a loading control. Results are representative of 3 experiments (C) HDMEC were transfected with a mixture of two siRNAs to individual PKC isoforms
and stimulated 48 hours post-transfection with VEGF-A (50 ng/ml) or PMA (100 nM) for 1 hour. Expression of RCAN1.4 mRNA, relative to
unstimulated (basal) N.S. transfected cells, was determined by RT-qPCR. Results were normalised to b-actin expression. Data shows mean 6 SD,
(n=3). *P,0.05, **P,0.01, versus N.S. treated cells. (D) HDMEC were transfected with a mixture of two siRNAs to individual PKC isoforms and
stimulated 48 hours post-transfection with VEGF (V; 50 ng/ml) or PMA (P; 100 nM) for 3 hours. Expression levels of RCAN1.4 protein were determined
by SDS-PAGE followed by western blotting. Actin was used as a loading control. Numbers below the blot denote the relative density of each band.
Results are representative of 3 experiments. (E) HDMEC, HUVEC and HAEC were transfected with two separate siRNAs to PKCd or N.S siRNA as
indicated, and stimulated 48 hours post-transfection with VEGF (50 ng/ml) for 3 hours. Expression levels of RCAN1.4 protein were determined by
SDS-PAGE followed by western blotting. Actin was used as a loading control. Numbers below the blots denote the relative density of each band.
Results are representative of 3 experiments.
doi:10.1371/journal.pone.0011435.g006
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upregulation occurs via VEGFR-2 signalling (Fig. 1C). No other
growth factor was found to induce RCAN1.4 expression (Fig. 1E
and 1F). Furthermore, VEGF-A was the only growth factor found
to phosphorylate PLC-c, and raise intracellular Ca
2+ (Fig. 1D/2B).
Although there is evidence that other growth factors, including
FGF-2 and EGF, are able to stimulate PLC-c activity in other cell
lines [40,41,42], it would appear that in primary HDMEC the
ability of VEGF to stimulate PLC-c activity is unique amongst
growth factors.
In addition to VEGF-A, PMA and A23187 were also found to
upregulate the expression of RCAN1.4. Treatment of HUVECs
with a combination of VEGF-A and PMA has previously been
shown to enhance the upregulation of RCAN1.4 [17]. The ability
Figure 7. RCAN1.4 regulates NFAT induced gene expression. (A) HDMEC were transfected with a mixture of two siRNAs to RCAN1 or non-
silencing (N.S.) siRNA and the knockdown of RCAN1.4 and effects on phospho-PLCc (p-PLCc) and phospho-p44/42 MAPK (pMAPK) were determined
by SDS-PAGE followed by western blotting. Actin was used as a loading control. Numbers below the blots denote the relative density of each band.
Results are representative of 3 experiments. (B) HDMEC were transfected with a mixture of two RCAN1 siRNAs and stimulated with VEGF-A (50 ng/ml)
for 1 hour. Expression of COX-2, IL-8 and ICAM-1 mRNA, relative to unstimulated (basal) untransfected cells, were determined by RT-qPCR. Results
were normalised to b-actin mRNA expression. Data shows mean 6 SD (n=3). **P,0.01, versus untransfected.
doi:10.1371/journal.pone.0011435.g007
Figure 8. RCAN1.4 is expressed during VEGF-mediated proliferation and tubular morphogenesis. (A) HDMEC were plated onto either a
collagen or gelatin matrix and stimulated with VEGF-A (50 ng/ml), FGF-2 (50 ng/ml), EGF (50 ng/ml) or FCS (10%), for the time points indicated.
Expression of RCAN1.4 mRNA, relative to unstimulated (basal) cells at 0 hr, was determined by RT-qPCR. Results were normalised to b-actin mRNA
expression. Data shows mean 6SD, (n=3). (B) HDMEC were treated as in 8(A), and the expression of RCAN1.4 protein determined by SDS-PAGE
followed by western blotting. Numbers below the blots denote the relative density of each band. Results are representative of 3 experiments.
doi:10.1371/journal.pone.0011435.g008
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PLoS ONE | www.plosone.org 9 July 2010 | Volume 5 | Issue 7 | e11435Figure 9. RCAN1.4 is required for migration and tubular morphogenesis, but not proliferation in HDMEC. (A) HDMEC were transfected
with a mixture of two siRNAs to RCAN1 or non-silencing (N.S.) siRNA and stimulated with VEGF-A (50 ng/ml) for 72 hours. Cellular proliferation was
determined by measuring viable cells. Data shows mean 6 SD, (n=3). (B) HDMEC were transfected with two individual siRNAs to RCAN1 or N.S. siRNA
as indicated. A scratch was introduced into the cell monolayer and the cells then stimulated with VEGF-A (50 ng/ml). Cells were fixed at 18 hours and
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noted in the literature [17,38], although to date the exact role of
PKC in the regulation of RCAN1.4 expression has not been
investigated.
Here we show that unlike VEGF-A, stimulation of HDMECs
with PMA does not result in the dephosphorylation of NFAT
(Fig. 1D). Furthermore, use of the calcineurin inhibitor CsA did
not inhibit PMA induced upregulation of RCAN1.4 (Fig. 4A).
Finally, we have shown that stimulation with PMA does not
induce a rise in intracellular Ca
2+, which is required for
calcineurin activity (Fig. 2B). Taken together, these data point
towards a secondary pathway, involving PKC, and independent
from the calcineurin pathway, which regulates RCAN1.4.
Profiling of the PKC isoforms in HDMECs detected the
expression of just 5 isoforms; the classical a, the novel d, e, and g
and the atypical i (Fig. 6A). VEGF-A was found to induce the
rapid phosphorylation of PKC a, d, e and g, with only PKCd
phosphorylation being sustained, whereas PMA induced sustained
activation of these PKC isoforms (Fig. 5). FGF-2 was found to only
weakly phosphorylate PKCe and g. This is the first data profiling
the temporal phosphorylation of multiple PKC isoforms in
response to VEGF-A and FGF-2 in human endothelial cells.
Activation of PKCd has been previously observed following
stimulation of endothelial cells with VEGF-A, and has been
implicated in Akt activation, and secretion of von Willebrand
factor (vWF) from endothelial cells, suggesting that PKCd may
regulate a number of pathways required for endothelial cell
function. [43,44]. Why the phosphorylation of PKCd is selectively
sustained in response to VEGF-A is unknown, but may be related
to the activation and interaction of other VEGF-A responsive
proteins with PKCd.
Targeted knockdown of these PKC isoforms using specific
siRNAs was performed to further identify which PKCs had a role
in RCAN1.4 upregulation (Fig. 6C–D). Following PKCd
knockdown VEGF-A induced RCAN1.4 was reduced at both
the mRNA and the protein level by approximately 50%,
suggesting that PKCd is able to regulate RCAN1.4 expression
in HDMEC. In contrast, PMA appears to preferentially use
PKCe, rather than PKCd, to regulate RCAN1.4 expression. This
is likely to be due to differences in kinetic profiles of phos-
fophorylated PKCs following stimulation by either VEGF-A or
PMA in HDMECs. In contrast to VEGF-A, PMA stimulates a
sustained phosphorylation of PKCe and g, and it is possible that
in this instance PKCe is able to regulate RCAN1.4 expression
independently of calcineurin mediated activation of NFAT.
PKCd was also found to be required for VEGF-A induced
RCAN1.4 expression in both HUVEC and HAEC confirming
that the importance of PKCd in VEGF-A signalling is not
confined to HDMEC (Fig. 6E).
The induction of RCAN1.4 by VEGF-A, but not PMA, was
inhibited by the use of the calcineurin inhibitor, CsA. Calcineurin
signalling is therefore necessary for RCAN1.4 induction by
VEGF-A. However, since knockdown of PKCd does not result
in the complete inhibition of RCAN1.4 induction by VEGF-A, it
would appear that signalling via PKCd may cooperate with the
calcineurin pathway to induce RCAN1.4 expression, probably by
regulating the activity of a transcription factor distinct from
NFAT. A recent study demonstrated that RCAN1.4 could be
upregulated by c-Jun, a component of the AP-1 complex [11].
However, it is unlikely that this is the pathway through which
PKC is acting as a known inhibitor of AP-1 activation, MEK1
inhibitor U0126 [30], was found not to affect VEGF or PMA
stimulated RCAN1.4 mRNA expression (Fig. 3).
Proliferation is an important process contributing towards
angiogenesis. The role of RCAN1.4 in proliferation is still
somewhat ambiguous. Overexpression of RCAN1 has been
stained with crystal violet. Bars=100 mm. The graph shows the extent of migration in response to VEGF-A relative to the untransfected condition.
Data shows mean 6 SD, (n=3). **P,0.01, versus untransfected (C) Cells were transfected with two individual siRNAs to RCAN1 or N.S. siRNA and
plated onto a collagen matrix, and stimulated with VEGF-A (50 ng/ml). Collagen gels were fixed at 20 hours to allow visualisation of tubes.
Bars=100 mm. The graph shows quantification of tubular morphogenesis as measured by the number of cellular junctions. Data shows mean 6 SD,
(n=3). **P,0.01, versus untransfected, VEGF treated. (D) Cells were cultured upon fibroblast lawns, and transfected with two individual siRNAs to
RCAN1 or N.S. siRNA. Cells were stimulated with VEGF-A (50 ng/ml) for 5 days. Cells were fixed and stained for the endothelial specific marker CD31 to
allow visualisation of tubes. Bars=100 mm. The graph shows quantification of tubular morphogenesis as measured by the number of cellular
junctions. Data shows mean 6 SD (n=3). **P,0.01, versus untransfected, VEGF treated.
doi:10.1371/journal.pone.0011435.g009
Figure 10. Summary of RCAN1.4 upregulation by VEGF-A in
HDMEC. VEGFR-2 activation leads to PLC-c activation and the
subsequent increase in intracellular Ca
2+ leading to activation of
calcineurin and NFAT, which gives rise to increased RCAN1.4 expression.
In addition, VEGFR-2 activation results in the sustained phosphorylation
of PKCd, which contributes to the upregulation of RCAN1.4 via an
unknown pathway. RCAN1.4 acts to regulate VEGFR-2 mediated cellular
migration and tubular morphogenesis.
doi:10.1371/journal.pone.0011435.g010
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knockdown of RCAN1.4 has been shown to increase endothelial
cell proliferation [39]. RCAN1.4 is thought to exert its effects
upon cellular proliferation via the regulation of calcineurin and
NFAT induced gene transcription. In our study we were not able
to detect an effect of RCAN1.4 knockdown upon proliferation
(Fig. 9A). A similar result has also been reported in HUVECs
[16]. A recently published study has shown that knockdown of
RCAN1.4 decreases MAPK activation and cellular prolifera-
tion in human U87MG glioblastoma cells, via a calcineurin
independent mechanism [45]. We do not observe any alterations
in MAPK signalling following RCAN1.4 knockdown (Fig. 7A),
which is consistent with the lack of effect of RCAN1.4 on cell
proliferation.
Directed endothelial cell migration in response to VEGF
stimulation represents one of the earliest steps in sprouting
angiogenesis [46]. Our data shows that RCAN1.4 is able to
regulate migration in HDMEC. RCAN1.4 has previously been
shown to have a role in angiogenesis in vitro, and in vivo [10,16].
Here we provide data to show that RCAN1.4 expression is
required for efficient tubular morphogenesis in a co-culture model
(Fig. 9D). Upon stimulation with VEGF-A, HDMEC undergo
tubular morphogenesis, which may be quantified using image
analysis software. Following knockdown of RCAN1.4 the ability of
HDMECs to undergo tubular morphogenesis was impaired.
Though the formation of tubular networks can still occur it would
appear that the cells are no longer equipped to fully respond to
VEGF-A stimulation. Similarly, HDMECs plated upon a collagen
gel were less able to form tubular networks in response to VEGF-A
following RCAN1.4 knockdown (Fig. 9C). Visual analysis of the
tubes upon a collagen gel shows that the tubes that are formed
appear to be less organised.
RCAN1.4 is known to have a role in the regulation of tumour
angiogenesis. Angiogenesis is a multi-step process requiring the
proteolytic digestion of the basement membrane, and co-ordinated
migration, proliferation, and finally differentiation of endothelial
cells into a lumen-containing vessel supported by pericytes [47].
Here we provide evidence that RCAN1.4 is required for the
coordination of specific components of angiogenesis.
It has been previously thought that VEGF induces RCAN1.4
via the activation of the Ca
2+/calcineurin/NFAT pathway. We
now provide evidence for a role of PKCd in the upregulation of
RCAN1.4 expression via an independent pathway (Fig. 10). In
addition, we show that VEGF appears unique amongst growth
factors in its ability to induce an increase in intracellular Ca
2+
levels, as well as sustained PKCd phosphorylation, both of which
contribute to the upregulation of RCAN1.4 expression in
endothelial cells.
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